奥马珠单抗注射治疗在过敏性疾病中的效果研究及护理体会  

Study on the efficacy of omalizumab injection in allergic diseases and nursing experience

作　　者：熊巍[1] 锡琳[2] 张媛[2] 张罗[3] Xiong Wei;Xi Lin;Zhang Yuan;Zhang Luo(Department of Otolaryngology Head and Neck Surgery,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Allergy,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Beijing Key Laboratory of Nasal Diseases,Beijing Institute of Otolaryngology,Beijing 100005,China)

机构地区：[1]首都医科大学附属北京同仁医院耳鼻咽喉头颈外科,北京100730 [2]首都医科大学附属北京同仁医院过敏科,北京100730 [3]北京市耳鼻咽喉科研究所鼻病研究北京市重点实验室,北京100005

出　　处：《中国实用护理杂志》2022年第27期2146-2150,共5页Chinese Journal of Practical Nursing

基　　金：国家自然科学基金面上项目(82071022)。

摘　　要：目的:通过观察奥马珠单抗对过敏性疾病患者的治疗效果,总结护理工作,进而指导完善相关的护理策略。方法:收集2018年10月至2020年9月在首都医科大学附属北京同仁医院过敏科接受奥马珠单抗治疗的108例过敏性疾病患者的病史、治疗基线血清总IgE水平、治疗前后临床症状视觉模拟量表(VAS)评分、治疗后患者总体印象变化(PGIC)。临床疗效以治疗前后肺部和鼻部症状的VAS评分的差异为主要评价指标。结果:注射奥马珠单抗无论是否足量均能改善鼻部及肺部症状(P<0.05),但注射足量的患者与注射不足量患者比较差异无统计学意义(P>0.05),注射次数与气短/呼吸困难的改善程度呈正相关(r=0.225,P<0.05)。注射足量的患者PGIC得分3.0(2.0,3.0)分,注射不足量的患者PGIC得分2.0(2.0,3.0)分,差异无统计学意义(Z=-0.73,P>0.05)。结论:注射奥马珠单抗能显著改善患者的鼻部及肺部症状,通过有效的护理干预策略提高患者的依从性,从而确保规范化治疗对患者临床症状的改善具有重要意义。Objective To guide the improvement of related nursing strategies by observing the therapeutic effect of omalizumab on patients with allergic diseases and summarizing the nursing work.Methods Collected the medical history,the total serum IgE level before the start of treatment,clinical symptoms Visual Analogue Scale(VAS)questionnaire,and the Patient Global Impression of Change(PGIC)after treatment of 108 patients with allergic diseases who received omalizumab in the Allergy Department of Beijing Tongren Hospital from October 2018 to September 2020.The clinical efficacy was mainly evaluated based on the VAS scores of lung and nasal symptoms before and after treatment.Results Omalizumab injection could significantly improve nasal and pulmonary symptoms whether the injection of omalizumab was sufficient or not(P<0.05),but there was o significant difference between the two(P>0.05).The number of injections was positively correlated with the improvement of shortness of breath/dyspnea(r=0.225,P<0.05).The PGIC score of patients with sufficient injection was 3.0(2.0,3.0)points,and that of patients with insufficient injection was 2.0(2.0,3.0)points,the difference was not statistically significant(Z=-0.73,P>0.05).Conclusions Injection of omalizumab can significantly improve the nasal and pulmonary symptoms of patients.Effective nursing intervention strategies can improve patient compliance,so as to ensure that standardized treatment is of great significance to the improvement of patients′clinical symptoms.

关 键 词：奥马珠单抗 过敏性疾病 护理 

分 类 号：R473.5[医药卫生—护理学]